Health
Organon to Present New Research on Access and Value at ISPOR 2026
JERSEY CITY, N.J., May 15, 2026--Organon to present 8 abstracts on affordability, access and adoption across women’s health, biosimilar and general medicines portfolio at ISPOR 2026.
About this update from Organon & Co.
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio JERSEY CITY, N.J., May 15, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. "Health economics and outcomes research is critical to ensuring the right treatments reach patients and that health systems can sustain this approach over time," said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. "At ISPOR 2026, Organon is proud to share research findings about the budget impact, referral patterns, and real-world evidence of treatments for contraception, dermatology, and neurology conditions—each grounded in evidence that puts patient and provider perspectives at the center." Key data from Organon’s portfolio to be presented include: Details on the abstracts noted above and additional presentations (including dates and times) can be found below. See below for full product information, including indication and selected safety information. About NEXPLANON® (etonogestrel implant) 68 mg Radiopaque Indication NEXPLANON® is indicated for prevention of pregnancy in women of reproductive potential for up to 5 years. Selected Safety Information WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION and REMOVAL Improper insertion of NEXPLANON increases the risk of complications. Proper training prior to first use of NEXPLANON can minimize the risk of improper NEXPLANON insertion. Because of the risk of complications due to improper insertion and removal NEXPLANON is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) ...